首页 > 市场调查报告书 > 製药

非专利药生技仿製药

市场调查报告书

商品编码

1529571

生物相似药市场：按药物类别、按治疗类型、按分销管道、按地区

Biosimilars Market, By Drug Class, By Therapy Type, By Distribution Channel, By Geography

出版日期: 2024年07月22日 | 出版商:

Coherent Market Insights | 英文 231 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计2024年全球生物相似药市场规模为360.1亿美元，预计2031年将达1,140.2亿美元，2024年至2031年复合年增长率为17.9%。

报告范围		报告详情
基准年	2023年	2024年市场规模	360.1亿美元
实际资料	2019-2023	预测期	2024-2031
2024-2031 年预测期复合年增长率	17.90%	2031 年金额预测	1140.2亿美元

图：按地区分類的生物相似药市场份额（%）（2024 年）

全球医疗保健成本上升和重磅生技药品专利到期推动了全球生物相似药市场的成长。生物相似药代表了癌症、糖尿病和自体免疫疾病等慢性疾病的一种经济实惠的治疗选择。与参考生技药品相比，生物相似药可显着节省成本。例如，Filgrastim的生物相似药 Zargio 的上市价格比原生技药品Neupogen 低 15%。此外，美国、欧盟和日本等主要市场对生物相似药的监管核准不断增加，并制定了明确的指导方针，使市场准入变得更加容易。出于这个原因，许多新兴企业正在进入庞大且利润丰厚的生物相似药市场。

市场动态：

全球生物相似药市场的成长是由全球慢性病盛行率上升和有限的医疗保健预算所推动的。这增加了对替代生技药品的低成本生物相似药的需求。预计许多重磅生技药品将在 2018 年至 2026 年预测期内失去专利保护，为生物相似药进入打开大门。例如，到 2023 年，Infliximab和Adalimumab将成为面临生物相似药竞争的收益最高的生技药品之一。主要参与者的监管核准、产品发布和行销扩张努力可能会推动市场成长。

本研究的主要特点

本报告对全球生物相似药市场进行了详细分析，并提供了以 2023 年为基准年的预测期（2024-2031 年）的市场规模（十亿美元）和年复合成长率（CAGR%）。。
它还揭示了各个细分市场的潜在商机，并说明了该市场有吸引力的投资提案矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。
它根据公司亮点、产品系列、主要亮点、财务表现和策略等参数，介绍了全球生物相似药市场的主要企业。
该报告的见解使负责人和公司经营团队能够就未来的产品发布、升级、市场扩张和行销策略做出明智的决策。
全球生物相似药市场报告迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
相关人员可以透过分析全球生物相似药市场时所使用的各种策略矩阵来促进决策。

公司简介
- Amgen Inc.
- Pfizer Inc.
- Samsung Bioepis Co., Ltd.
- Sandoz International GmbH
- Celltrion Healthcare Co., Ltd.
- Biocon Limited
- Dr. Reddy's Laboratories Ltd.
- Teva Pharmaceutical Industries Ltd.
- Boehringer Ingelheim International GmbH
- Fresenius Kabi AG
- Merck &Co., Inc.
- Biogen Idec Inc
- Coherus BioSciences
- Stada Arzneimittel AG

第10章分析师建议

上升和下降
综合机会图

第十一章参考文献与调查方法

参考
调查方法

简介目录

Product Code: CMI750

Global biosimilars market is estimated to be valued at USD 36.01 Bn in 2024 and is expected to reach USD 114.02 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 17.9% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2024:	US$ 36.01 Bn
Historical Data for:	2019 to 2023	Forecast Period:	2024 to 2031
Forecast Period 2024 to 2031 CAGR:	17.90%	2031 Value Projection:	US$ 114.02 Bn

Figure. Biosimilars Market Share (%), By Region 2024

Global biosimilars market growth is driven by rising healthcare costs worldwide and the expiration of blockbuster biologics patents. Biosimilars provide affordable treatment options for chronic diseases such as cancer, diabetes, and autoimmune disorders. These offer significant cost savings as compared to reference biologics. For example, Filgrastim's biosimilar Zarzio was launched at a 15% lower price compared to original biologic Neupogen. Regulatory approvals for biosimilars have also increased in major markets like the U.S, EU, and Japan following clear guidelines, thus, easing market entry. This has attracted many emerging players to the large and lucrative biosimilars market.

Market Dynamics:

Global biosimilars market growth is driven by factors like rising chronic disease prevalence rates worldwide coupled with limited healthcare budgets. This has boosted demand for lower-cost biosimilar alternatives to biologics. Many blockbusters biologic drugs are expected to lose patent protection over the forecast period 2018-2026, thus, offering potential for biosimilar entrants. For instance, infliximab and adalimumab are among the highest revenue earning biologics that faced biosimilar competition by 2023. Regulatory approvals and product launches, along with marketing expansion activities by major players can drive the market growth.

Key Features of the Study:

This report provides in-depth analysis of the global biosimilars market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global biosimilars market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Novartis, Pfizer, Teva Pharmaceuticals, Celltrion, Biocon, Amgen, Samsung Biologics, Stada Arzneimittel AG.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
Global biosimilars market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global biosimilars market.

Detailed Segmentation-

By Drug Class
- Recombinant Human Growth Hormone
- Granulocyte Colony-Stimulating Factor
- Insulin
- Anticoagulants
- Fusion Proteins Erythropoietin
- Monoclonal Antibodies
- Follitropin
- Others
By Therapy Type
- Oncology
- Immunology
- Hematology
- Hormone Therapy
- Metabolic Disorders
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Specialty Pharmacies
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Amgen Inc.
- Pfizer Inc.
- Samsung Bioepis Co., Ltd.
- Sandoz International GmbH
- Celltrion Healthcare Co., Ltd.
- Biocon Limited
- Reddy's Laboratories Ltd.
- Teva Pharmaceutical Industries Ltd.
- Boehringer Ingelheim International GmbH
- Fresenius Kabi AG
- Merck & Co., Inc.
- Biogen Idec Inc
- Coherus BioSciences
- Stada Arzneimittel AG

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Therapy Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Market Trends
Key Developments
Regulatory Scenario
Acquisitions and Partnerships Scenario
Funding and Investments
PEST Analysis
Porter's Analysis

4. Global Biosimilars Market - Impact of Coronavirus (COVID-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the Market

5. Global Biosimilars Market, By Drug Class, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Recombinant Human Growth Hormone
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Granulocyte Colony-Stimulating Factor
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Insulin
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Anticoagulants
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Fusion Proteins Erythropoietin
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Monoclonal Antibodies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Follitropin
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Biosimilars Market, By Therapy Type, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Oncology
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Immunology
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Hematology
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Hormone Therapy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Metabolic Disorders
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Biosimilars Market, By Distribution Channel, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Specialty Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Biosimilars Market, By Region, 2019 - 2031, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2019-2031
- Regional Trends
  - North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
  - Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Company Profiles
- Amgen Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Pfizer Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Samsung Bioepis Co., Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Sandoz International GmbH
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Celltrion Healthcare Co., Ltd.
- Biocon Limited
- Dr. Reddy's Laboratories Ltd.
- Teva Pharmaceutical Industries Ltd.
- Boehringer Ingelheim International GmbH
- Fresenius Kabi AG
- Merck & Co., Inc.
- Biogen Idec Inc
- Coherus BioSciences
- Stada Arzneimittel AG

10. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

11. References and Research Methodology

References
Research Methodology
About us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/价格

生物相似药市场：按药物类别、按治疗类型、按分销管道、按地区